We are live on ! Find out more

Medpace

MEDP

Market cap $17.2B

617.80 USD

+15.10

2.51%

At close Updated Oct 9, 2:24 PM EDT

1 day

2.51%

5 days

2.63%

1 month

5.37%

3 months

15.37%

6 months

23.19%

Year to date

8.19%

1 year

19.11%

5 years

235.07%

10 years

1,942.31%

About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Employees: 6,500

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 69.7%

Neutral 30.3%

Negative 0%

Zacks Investment Research

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Zacks Investment Research

Medpace (MEDP) Rises As Market Takes a Dip: Key Facts

In the closing of the recent trading day, Medpace (MEDP) stood at $622.11, denoting a +1% move from the preceding trading day.

Medpace (MEDP) Rises As Market Takes a Dip: Key Facts

Zacks Investment Research

CON or MEDP: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

CON or MEDP: Which Is the Better Value Stock Right Now?

Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended yo.

Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026

Zacks Investment Research

Medpace (MEDP) Outperforms Broader Market: What You Need to Know

Medpace (MEDP) concluded the recent trading session at $624.2, signifying a +1.94% move from its prior day's close.

Medpace (MEDP) Outperforms Broader Market: What You Need to Know

Zacks Investment Research

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Medpace (MEDP) closed at $595.41, marking a +1.34% move from the previous day.

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

Zacks Investment Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Investment Research

Why Medpace (MEDP) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Medpace (MEDP) is a Top Growth Stock for the Long-Term

Investors Business Daily

Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike

Medpace stock is back below a buy point of 628.92. The medical research contractor delivered an earnings beat for its second quarter.

Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike

Zacks Investment Research

CON vs. MEDP: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

CON vs. MEDP: Which Stock Should Value Investors Buy Now?

See News Rankings

Price charts implemented using Lightweight Charts™